TriSalus (TLSI) Q1 2026 earnings review
Growth Story Hits a Wall: Sales Reverse and Guidance Slashed
After stringing together consecutive quarters of 40-60% revenue growth, TriSalus delivered a shock in 26Q1 with a 2.9% YoY revenue contraction. The sudden reversal is being blamed on self-inflicted wounds—specifically, disruptions from the aggressive commercial expansion strategy detailed in prior quarters—coupled with delayed FDA clearance for the new TriNav Advance device. While gross margins improved and the balance sheet was fortified with a $46M capital raise, the core growth narrative has been severely dented. Management slashed FY26 revenue guidance from $60-62M down to $54-57M, acknowledging that the path to scale is bumpier than anticipated.
🐂 Bull Case
The company successfully raised $46M in equity, ending the quarter with $56.6M in cash. This provides sufficient runway to weather the current operational disruption and fully fund the commercial expansion without immediate dilution risk.
Gross margins actually accelerated to 86.2% from 83.7% a year ago due to lower average unit costs. If volume returns, the profit flow-through will be highly efficient.
🐻 Bear Case
The abrupt transition from 60% growth to a YoY decline highlights severe execution risks in their strategy to double the salesforce. Territory realignments are actively hurting current sales.
The delayed FDA clearance for TriNav Advance removes a key growth driver for the first half of the year, directly forcing a material cut to FY26 guidance.
⚖️ Verdict: 🔴
Bearish. A 60% growth rate dropping instantly to negative 3% is a major red flag, regardless of the excuse. When combined with a guidance cut and regulatory delays, management will be in the penalty box until they prove the commercial expansion is actually generating a return on investment.
Key Themes
Commercial Disruption Derails Growth
Revenue growth went from Accelerating (+60% in 25Q4) to abruptly Reversing (-2.9% in 26Q1). Management explicitly blamed the revenue drop on their 'commercial expansion.' During the Q4 call, they outlined a plan to 'virtually double' the salesforce. This disruption—likely stemming from territory realignments, training, and breaking established physician relationships—is actively cannibalizing near-term sales.
TriNav Advance FDA Clearance Delayed
A specific, tangible setback: FDA clearance for TriNav Advance is delayed. This next-generation device, designed to extend PEDD capability to small distal vessels via a microcatheter, was previously slated as a key H1 2026 launch to drive adoption. This regulatory bottleneck was cited as a primary reason for the downward revision in annual guidance.
Operating Burn Remains Elevated
Despite the drop in sales, expenses are still climbing. Operating loss expanded from $7.3M to $8.4M YoY, driven heavily by a jump in Sales & Marketing to $7.4M. Adjusted EBITDA loss slightly worsened to $5.8M. The timeline to EBITDA positivity, which was already pushed out in prior quarters to 'late 2026', now looks even more precarious given the top-line miss.
Landmark Real-World Data Validates Economics
TriSalus published a massive real-world PEDD study comparing 603 PEDD patients against 16,210 non-PEDD patients. The data showed fewer post-procedure complications, reduced hospitalizations, and roughly $7,700 in per-patient charge avoidance. This arms the salesforce with undeniable health economics and outcomes research (HEOR) to justify the technology's cost to hospital value analysis committees.
Expanding Clinical Body of Evidence
Beyond the liver, TriSalus presented new clinical data at the 2026 Society of Interventional Radiology Annual Scientific Meeting. Data covered neuroendocrine tumor liver metastases and, crucially, uterine artery embolization (UAE). Proving efficacy in UAE is vital for expanding their total addressable market beyond oncology and into benign conditions.
Unit Economics Showing Operating Leverage
A bright spot in the quarter: Gross margin is Accelerating, reaching 86.2% compared to 83.7% in the prior year. Management noted this was due to a lower average cost per TriNav unit. If the company can fix its commercial execution and return to volume growth, the flow-through to the bottom line will be highly efficient.
Other KPIs
This positive Net Income figure is an accounting mirage that contradicts the deteriorating operational reality. The positive result was driven entirely by an $11.3M non-cash gain related to changes in the fair value of derivatives and contingent earnouts. The true gauge of core performance—Operating Loss—was negative $8.4M.
Up massively from $20.4M at the end of 2025. The company raised $46M in gross proceeds during the quarter. This liquidity is critical; at the current Adjusted EBITDA burn rate of ~$5.8M per quarter, the company has several years of runway to correct its commercial missteps.
Guidance
Decelerating. Management slashed the prior guidance of $60-62M. At the new midpoint ($55.5M), implied YoY growth over FY25 ($45.2M) is roughly 23%. This is a severe deceleration from the 53% growth achieved in FY25. Management explicitly tied this cut to the dual headwinds of commercial expansion disruptions and the FDA delay for TriNav Advance.
Key Questions
Duration of Commercial Disruption
You cited commercial expansion as the primary driver for the revenue decline. What specific metrics give you confidence that this is a temporary disruption from territory realignment rather than a permanent loss of account momentum, and when exactly do you expect the new sales reps to become fully productive?
TriNav Advance FDA Delay Specifics
Regarding the delayed FDA clearance for TriNav Advance, what specific feedback or requests for additional information have you received from the agency, and what is your revised base-case timeline for commercial launch?
Nelitolimod Partnership Update
In previous quarters, management heavily promoted the strategic shift to partner the nelitolimod program by the end of 2025 to eliminate R&D spend. There was no mention of this in the current release. Has the timeline or expected economics for this partnership changed?